Naruyasu Kakita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Naruyasu Kakita has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Kazuhiro Katayama
Department of Gastroenterology and Hepatology Kaizuka City Hospital Osaka Japan
4 shared publications- Hayato Hikita
Department of Gastroenterology and Hepatology The University of Osaka Graduate School of Medicine Suita Osaka Japan
3 shared publications Kenji Aoi
Department of Gastroenterology and Hepatology Kaizuka City Hospital Osaka Japan
3 shared publicationsShin Satake
Department of Gastroenterology and Hepatology Kaizuka City Hospital Osaka Japan
3 shared publications- Takahiro Kodama
Department of Gastroenterology and Hepatology The University of Osaka Graduate School of Medicine Suita Osaka Japan
3 shared publications - Tetsuo Takehara
Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Japan
3 shared publications
Latest Publications
- Open Access
- 2 August 2026
- Published by Wiley in Hepatology Research
Serum Agalactosyl IgG Predicts Hepatocellular Carcinoma and All‐Cause Mortality After SVR in Advanced Chronic Hepatitis C
Background and Aims: Patients with chronic hepatitis C and advanced fibrosis remain at substantial risk of hepatocellular carcinoma (HCC) and non‐liver–related death even after sustained virological response (SVR) to direct‐acting antivirals (DAA). Serum agalactosyl IgG (agal‐IgG) reflects chronic inflammation and fibrogenic activity, but its prognostic value after SVR is unknown. We investigated whether serum agal‐IgG at end of treatment (EOT) predicts HCC and all‐cause mortality in DAA‐treated patients with advanced fibrosis. Methods: Among 3550 patients with chronic hepatitis C treated with DAAs at Osaka University Hospital and affiliated centers, the stored sera of 136 patients with biopsy‐proven F3–F4 fibrosis before DAA treatment, who achieved SVR, and had no history of HCC were available at EOT. Serum agal‐IgG at EOT was measured using a 42B1‐based ELISA. Results: During a median follow‐up of 68.7 months (interquartile range, 36.8–84.9) for HCC surveillance, 15 patients developed HCC. Over a median overall follow‐up of 73.7 months (54.5–86.7), 11 patients died. Higher EOT agal‐IgG levels were significantly associated with both HCC occurrence and all‐cause mortality, and these associations remained independent after adjustment for age, sex, and baseline fibrosis (FIB‐4 index). The adjusted hazard ratios per 1‐unit increase in agal‐IgG were 1.050 (95% CI, 1.008–1.094) for HCC and 1.085 (95% CI, 1.035–1.137) for all‐cause mortality. Patients with EOT agal‐IgG levels above the cohort median also showed significantly higher cumulative incidences of HCC and all‐cause death than those with lower levels. Conclusions: Serum agalactosyl IgG measured at the end of DAA therapy independently predicts HCC and all‐cause mortality after SVR in patients with chronic hepatitis C and advanced fibrosis. EOT agal‐IgG may offer additional prognostic information for post‐SVR risk stratification and help identify patients at higher risk of HCC and all‐cause mortality after SVR.
- 2 August 2026
- Published by Wiley in Hepatology Research
Open AccessSerum Agalactosyl IgG Predicts Hepatocellular Carcinoma and All‐Cause Mortality After SVR in Advanced Chronic Hepatitis C
Background and Aims: Patients with chronic hepatitis C and advanced fibrosis remain at substantial risk of hepatocellular carcinoma (HCC) and non‐liver–related death even after sustained virological response (SVR) to direct‐acting antivirals (DAA). Serum agalactosyl IgG (agal‐IgG) reflects chronic inflammation and fibrogenic activity, but its prognostic value after SVR is unknown. We investigated whether serum agal‐IgG at end of treatment (EOT) predicts HCC and all‐cause mortality in DAA‐treated patients with advanced fibrosis. Methods: Among 3550 patients with chronic hepatitis C treated with DAAs at Osaka University Hospital and affiliated centers, the stored sera of 136 patients with biopsy‐proven F3–F4 fibrosis before DAA treatment, who achieved SVR, and had no history of HCC were available at EOT. Serum agal‐IgG at EOT was measured using a 42B1‐based ELISA. Results: During a median follow‐up of 68.7 months (interquartile range, 36.8–84.9) for HCC surveillance, 15 patients developed HCC. Over a median overall follow‐up of 73.7 months (54.5–86.7), 11 patients died. Higher EOT agal‐IgG levels were significantly associated with both HCC occurrence and all‐cause mortality, and these associations remained independent after adjustment for age, sex, and baseline fibrosis (FIB‐4 index). The adjusted hazard ratios per 1‐unit increase in agal‐IgG were 1.050 (95% CI, 1.008–1.094) for HCC and 1.085 (95% CI, 1.035–1.137) for all‐cause mortality. Patients with EOT agal‐IgG levels above the cohort median also showed significantly higher cumulative incidences of HCC and all‐cause death than those with lower levels. Conclusions: Serum agalactosyl IgG measured at the end of DAA therapy independently predicts HCC and all‐cause mortality after SVR in patients with chronic hepatitis C and advanced fibrosis. EOT agal‐IgG may offer additional prognostic information for post‐SVR risk stratification and help identify patients at higher risk of HCC and all‐cause mortality after SVR.
- 19 June 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (10) , 1547-1555
Hepatologist‐Driven Screening for Obstructive Sleep Apnea in Patients With MASLD Using a Modified STOP‐Bang Questionnaire: The SOMA Model
Aim: To evaluate the feasibility, diagnostic yield, and downstream clinical linkage of a hepatologist‐driven obstructive sleep apnea (OSA) screening pathway using a modified STOP‐Bang questionnaire in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). Methods: From July 2025 to March 2026, 555 outpatients with MASLD were screened using the Screening for OSA in MASLD (SOMA) model. Home sleep apnea testing (HSAT) referral relied on the modified STOP‐Bang questionnaire, Epworth Sleepiness Scale (ESS), and clinical judgment. Among 276 HSAT‐evaluated patients, 258 with valid recordings were analyzed. Clinically significant OSA was defined as a respiratory event index (REI) ≥ 15 events/hour. Results: Among HSAT‐evaluated outpatients with MASLD, OSA (REI ≥ 5 events/hour) and clinically significant OSA occurred in 253 (98.1%) and 203 (78.7%), respectively. The modified STOP‐Bang questionnaire outperformed the ESS (area under the curve: 0.616 vs. 0.485, p = 0.021). A modified STOP‐Bang score ≥ 3 showed high sensitivity (93.6%) but low specificity (7.3%), whereas a score ≥ 5 showed more balanced sensitivity (59.1%) and specificity (54.5%). ESS score ≥ 11 showed poor sensitivity (10.8%). Among patients with REI ≥ 15 and ≥ 30 events/hour, full polysomnography was completed or scheduled in 64.0% and 73.0%, respectively. OSA severity was not significantly associated with Fibrosis‐4 index, Mac‐2 binding protein glycosylation isomer levels, or shear wave elastography findings. Conclusions: Clinically significant OSA was frequent among selected HSAT‐evaluated MASLD outpatients. The SOMA model may represent a feasible hepatologist‐driven screening/referral pathway integrating structured triage, clinical judgment, and HSAT. However, these findings should not be interpreted as prevalence estimates or evidence of long‐term clinical benefit.
- 19 June 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (10) , 1547-1555
Hepatologist‐Driven Screening for Obstructive Sleep Apnea in Patients With MASLD Using a Modified STOP‐Bang Questionnaire: The SOMA Model
Aim: To evaluate the feasibility, diagnostic yield, and downstream clinical linkage of a hepatologist‐driven obstructive sleep apnea (OSA) screening pathway using a modified STOP‐Bang questionnaire in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). Methods: From July 2025 to March 2026, 555 outpatients with MASLD were screened using the Screening for OSA in MASLD (SOMA) model. Home sleep apnea testing (HSAT) referral relied on the modified STOP‐Bang questionnaire, Epworth Sleepiness Scale (ESS), and clinical judgment. Among 276 HSAT‐evaluated patients, 258 with valid recordings were analyzed. Clinically significant OSA was defined as a respiratory event index (REI) ≥ 15 events/hour. Results: Among HSAT‐evaluated outpatients with MASLD, OSA (REI ≥ 5 events/hour) and clinically significant OSA occurred in 253 (98.1%) and 203 (78.7%), respectively. The modified STOP‐Bang questionnaire outperformed the ESS (area under the curve: 0.616 vs. 0.485, p = 0.021). A modified STOP‐Bang score ≥ 3 showed high sensitivity (93.6%) but low specificity (7.3%), whereas a score ≥ 5 showed more balanced sensitivity (59.1%) and specificity (54.5%). ESS score ≥ 11 showed poor sensitivity (10.8%). Among patients with REI ≥ 15 and ≥ 30 events/hour, full polysomnography was completed or scheduled in 64.0% and 73.0%, respectively. OSA severity was not significantly associated with Fibrosis‐4 index, Mac‐2 binding protein glycosylation isomer levels, or shear wave elastography findings. Conclusions: Clinically significant OSA was frequent among selected HSAT‐evaluated MASLD outpatients. The SOMA model may represent a feasible hepatologist‐driven screening/referral pathway integrating structured triage, clinical judgment, and HSAT. However, these findings should not be interpreted as prevalence estimates or evidence of long‐term clinical benefit.
- Open Access
- 26 May 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (6)
Monocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy
Background: Although nucleos(t)ide analogs (NAs) suppress HBV replication, functional cure—defined by hepatitis B surface antigen (HBsAg) loss—is rarely achieved in chronic hepatitis B (CHB). Immune correlates of HBsAg decline may inform new therapeutic strategies. Methods: We profiled peripheral blood mononuclear cells (PBMCs) from NA-treated CHB patients with declining versus sustained HBsAg levels by single-cell RNA sequencing (scRNA-seq), followed by validation in an independent multicenter cohort using transcriptomic and functional assays. In a retrospective cohort, we evaluated serum interleukin-1β (IL-1β) as a predictor of HBsAg decline during long-term follow-up. Results: scRNA-seq revealed that CD14 + CD16 − classical monocytes in the HBsAg-declining group expressed significantly higher levels of IL-1β, along with genes involved in antigen presentation and phagocytosis. In the validation cohort, IL-1β expression in circulating CD14 + classical monocytes was also significantly higher in the declining group. Ex vivo stimulation assays demonstrated that recombinant HBsAg induced IL-1β production in monocytes, with stronger responses in the declining group. Recombinant IL-1β suppressed HBsAg secretion from HBV-producing HepG2.2.15 cells in vitro in a dose-dependent manner. In a longitudinal cohort, elevated serum IL-1β predicted subsequent HBsAg decline with an AUROC of 0.71. Multivariate analysis confirmed IL-1β as an independent predictor. Conclusions: Monocyte-derived IL-1β is linked to HBsAg decline during NA therapy and may serve as both a predictive biomarker and a potential therapeutic target to achieve functional cure.
- 26 May 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (6)
Open AccessMonocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy
Background: Although nucleos(t)ide analogs (NAs) suppress HBV replication, functional cure—defined by hepatitis B surface antigen (HBsAg) loss—is rarely achieved in chronic hepatitis B (CHB). Immune correlates of HBsAg decline may inform new therapeutic strategies. Methods: We profiled peripheral blood mononuclear cells (PBMCs) from NA-treated CHB patients with declining versus sustained HBsAg levels by single-cell RNA sequencing (scRNA-seq), followed by validation in an independent multicenter cohort using transcriptomic and functional assays. In a retrospective cohort, we evaluated serum interleukin-1β (IL-1β) as a predictor of HBsAg decline during long-term follow-up. Results: scRNA-seq revealed that CD14 + CD16 − classical monocytes in the HBsAg-declining group expressed significantly higher levels of IL-1β, along with genes involved in antigen presentation and phagocytosis. In the validation cohort, IL-1β expression in circulating CD14 + classical monocytes was also significantly higher in the declining group. Ex vivo stimulation assays demonstrated that recombinant HBsAg induced IL-1β production in monocytes, with stronger responses in the declining group. Recombinant IL-1β suppressed HBsAg secretion from HBV-producing HepG2.2.15 cells in vitro in a dose-dependent manner. In a longitudinal cohort, elevated serum IL-1β predicted subsequent HBsAg decline with an AUROC of 0.71. Multivariate analysis confirmed IL-1β as an independent predictor. Conclusions: Monocyte-derived IL-1β is linked to HBsAg decline during NA therapy and may serve as both a predictive biomarker and a potential therapeutic target to achieve functional cure.
- 18 July 2025
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 18 (5) , 931-937
Histopathological changes in two patients with hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease treated with pemafibrate: a serial liver biopsy study
This study investigated histological liver-tissue changes before and after 1 year of pemafibrate treatment in two women with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia who were refractory to ≥ 6 months of lifestyle intervention. The patients underwent paired liver biopsies before and after receiving pemafibrate (0.2 mg, once daily) for 52 weeks. Improvements in the non-alcoholic fatty liver disease activity score and fibrosis stage were examined. In Case 1, pre-treatment liver biopsy revealed 90% steatosis, ballooning, lobular inflammation, and fibrosis (Brunt grade 2, stage 3). Post-treatment, steatosis decreased to 50%, ballooning and inflammation resolved, and fibrosis improved (grade 1, stage 2). In Case 2, pre-treatment liver biopsy showed 70% steatosis, mild lobular inflammation, and fibrosis (grade, 1, stage 3). Post-treatment, steatosis increased to 90%, inflammation resolved, and fibrosis improved (grade 1, stage 1). The fibrosis-4 index improved in both cases; however, shear wave elastography showed no improvement. Pemafibrate may exert antifibrotic and anti-inflammatory effects in MASLD regardless of steatosis trends and that histological assessment remains crucial, especially when non-invasive markers provide inconsistent results. This is the first report to confirm histopathological improvement with pemafibrate via serial liver biopsy, offering important insights into its therapeutic potential for MASLD with dyslipidemia.
- 18 July 2025
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 18 (5) , 931-937
Histopathological changes in two patients with hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease treated with pemafibrate: a serial liver biopsy study
This study investigated histological liver-tissue changes before and after 1 year of pemafibrate treatment in two women with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia who were refractory to ≥ 6 months of lifestyle intervention. The patients underwent paired liver biopsies before and after receiving pemafibrate (0.2 mg, once daily) for 52 weeks. Improvements in the non-alcoholic fatty liver disease activity score and fibrosis stage were examined. In Case 1, pre-treatment liver biopsy revealed 90% steatosis, ballooning, lobular inflammation, and fibrosis (Brunt grade 2, stage 3). Post-treatment, steatosis decreased to 50%, ballooning and inflammation resolved, and fibrosis improved (grade 1, stage 2). In Case 2, pre-treatment liver biopsy showed 70% steatosis, mild lobular inflammation, and fibrosis (grade, 1, stage 3). Post-treatment, steatosis increased to 90%, inflammation resolved, and fibrosis improved (grade 1, stage 1). The fibrosis-4 index improved in both cases; however, shear wave elastography showed no improvement. Pemafibrate may exert antifibrotic and anti-inflammatory effects in MASLD regardless of steatosis trends and that histological assessment remains crucial, especially when non-invasive markers provide inconsistent results. This is the first report to confirm histopathological improvement with pemafibrate via serial liver biopsy, offering important insights into its therapeutic potential for MASLD with dyslipidemia.
- 7 February 2024
- Published by Wiley in Hepatology Research
- Vol. 54 (3) , 235-243
Possible pathogenetic role of ammonia in liver cirrhosis without hyperammonemia of venous blood: The so‐called latency period of abnormal ammonia metabolism
Ammonia plays a crucial role in the pathogenesis of hepatic encephalopathy. Ammonia is also involved in many other pathological conditions seen in cirrhosis, such as sarcopenia, liver fibrosis, hepatocellular injury, immune dysfunction, and hyperammonemia. Furthermore, the ammonia level of the veins is a useful prognostic factor for cirrhosis. In cirrhosis without hyperammonemia of the vein, however, covert hepatic encephalopathy has been reported. This discrepancy is because of the anatomical features of ammonia metabolism. There are two systems in the body for detoxifying ammonia: one is the urea cycle in the liver, and the other is the glutamine synthesis pathway in skeletal muscle and other tissues. The blood processed in the liver's urea cycle is then transported via arteries to various organs. Further processing occurs in the brain and skeletal muscle's glutamine synthesis pathway before entering the veins. When the urea cycle function decreases in cirrhosis, the ammonia levels in the artery increase. In response, the glutamine synthesis pathway compensates by increasing the capacity to process ammonia. Therefore, the ammonia concentration in the veins downstream of skeletal muscles does not increase immediately. However, the brain and skeletal muscles, which receive arterial blood, might be exposed to high ammonia concentrations. In addition, branched‐chain amino acids in venous blood decrease. This period is the transition phase from early‐ to late‐phase cirrhosis, and understanding the pathophysiology during this stage is extremely important for preventing the progression of cirrhosis.
- 7 February 2024
- Published by Wiley in Hepatology Research
- Vol. 54 (3) , 235-243
Possible pathogenetic role of ammonia in liver cirrhosis without hyperammonemia of venous blood: The so‐called latency period of abnormal ammonia metabolism
Ammonia plays a crucial role in the pathogenesis of hepatic encephalopathy. Ammonia is also involved in many other pathological conditions seen in cirrhosis, such as sarcopenia, liver fibrosis, hepatocellular injury, immune dysfunction, and hyperammonemia. Furthermore, the ammonia level of the veins is a useful prognostic factor for cirrhosis. In cirrhosis without hyperammonemia of the vein, however, covert hepatic encephalopathy has been reported. This discrepancy is because of the anatomical features of ammonia metabolism. There are two systems in the body for detoxifying ammonia: one is the urea cycle in the liver, and the other is the glutamine synthesis pathway in skeletal muscle and other tissues. The blood processed in the liver's urea cycle is then transported via arteries to various organs. Further processing occurs in the brain and skeletal muscle's glutamine synthesis pathway before entering the veins. When the urea cycle function decreases in cirrhosis, the ammonia levels in the artery increase. In response, the glutamine synthesis pathway compensates by increasing the capacity to process ammonia. Therefore, the ammonia concentration in the veins downstream of skeletal muscles does not increase immediately. However, the brain and skeletal muscles, which receive arterial blood, might be exposed to high ammonia concentrations. In addition, branched‐chain amino acids in venous blood decrease. This period is the transition phase from early‐ to late‐phase cirrhosis, and understanding the pathophysiology during this stage is extremely important for preventing the progression of cirrhosis.
- 5 December 2023
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 82, 127354
Zinc transporter 1 expression in hepatocellular carcinoma correlates with prognosis: A single-center retrospective study
- 5 December 2023
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 82, 127354
Zinc transporter 1 expression in hepatocellular carcinoma correlates with prognosis: A single-center retrospective study
- Open Access
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral
We evaluated the value of secreted glycoprotein thrombospondin-2 (TSP-2) to predict hepatocellular carcinoma (HCC) occurrence in chronic hepatitis C (CHC) patients after Hepatitis C virus (HCV) elimination by direct-acting antiviral agents (DAAs). A total of 786 CHC patients without an HCC history who achieved a sustained virological response (SVR) with DAAs were randomly assigned 2:1, with 524 patients as the derivation cohort and 262 patients as the validation cohort. Serum TSP-2 levels at the end of treatment were measured by enzyme-linked immunosorbent assay (ELISA). In the derivation cohort, the cumulative HCC rate was significantly higher in the high TSP-2 group than in the low TSP-2 group. Multivariate Cox proportional hazards analysis revealed that TSP-2, α-fetoprotein (AFP), and the fibrosis-4 (FIB-4) index were independent HCC risk factors. The area under the receiver operating characteristic curve (AUROC) of the score calculated from these three factors (AFT score) for predicting HCC was 0.83, which was significantly higher than that of each factor alone (TSP-2: 0.70, AFP: 0.72, FIB-4: 0.69). The AFT score was used to stratify patients according to the risk of HCC occurrence in the validation cohort. Lastly, in patients with a FIB-4 index < 3.25, the serum TSP-2 levels could be used to identify those patients with a high risk of HCC occurrence. Serum TSP-2 levels are a predictive biomarker of HCC occurrence in CHC patients after HCV elimination by DAA treatment. The AFT score using TSP-2, AFP, and the FIB-4 index may identify those who require HCC surveillance.
Open AccessThrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral
We evaluated the value of secreted glycoprotein thrombospondin-2 (TSP-2) to predict hepatocellular carcinoma (HCC) occurrence in chronic hepatitis C (CHC) patients after Hepatitis C virus (HCV) elimination by direct-acting antiviral agents (DAAs). A total of 786 CHC patients without an HCC history who achieved a sustained virological response (SVR) with DAAs were randomly assigned 2:1, with 524 patients as the derivation cohort and 262 patients as the validation cohort. Serum TSP-2 levels at the end of treatment were measured by enzyme-linked immunosorbent assay (ELISA). In the derivation cohort, the cumulative HCC rate was significantly higher in the high TSP-2 group than in the low TSP-2 group. Multivariate Cox proportional hazards analysis revealed that TSP-2, α-fetoprotein (AFP), and the fibrosis-4 (FIB-4) index were independent HCC risk factors. The area under the receiver operating characteristic curve (AUROC) of the score calculated from these three factors (AFT score) for predicting HCC was 0.83, which was significantly higher than that of each factor alone (TSP-2: 0.70, AFP: 0.72, FIB-4: 0.69). The AFT score was used to stratify patients according to the risk of HCC occurrence in the validation cohort. Lastly, in patients with a FIB-4 index < 3.25, the serum TSP-2 levels could be used to identify those patients with a high risk of HCC occurrence. Serum TSP-2 levels are a predictive biomarker of HCC occurrence in CHC patients after HCV elimination by DAA treatment. The AFT score using TSP-2, AFP, and the FIB-4 index may identify those who require HCC surveillance.